Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Ani S. Balmanoukian Clear advanced filters

  • In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in combination with the anti-PD-L1 agent atezolizumab, showing long-lasting neoantigen-specific immune responses and preliminary clinical activity, supporting further development of this therapeutic approach.

    • Juanita Lopez
    • Thomas Powles
    • D. Ross Camidge
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 152-164

  • In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in patients with relapsed/refractory microsatellite stable colorectal cancer, a tumor type typically unresponsive to immune checkpoint blockade.

    • Andrea J. Bullock
    • Benjamin L. Schlechter
    • Anthony B. El-Khoueiry
    ResearchOpen Access
    Nature Medicine
    Volume: 30, P: 2558-2567